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Primary cutaneous cd T-cell lymphoma (PCGD-TCL) is an aggressive lymphoma con-
sisting of clonal proliferation of mature activated cd T-cells of a cytotoxic pheno-
type. Because primary cutaneous cd T-cell lymphoma is a rare disease, there are
few clinicopathological studies. In addition, T-cell receptor (TCR) cd cells are typi-
cally immunostained in frozen sections or determined by TCRb negativity. We retro-
spectively analyzed 17 primary cutaneous T-cell lymphomas of the cd phenotype
(CTCL-cd) in a clinicopathological and molecular study using paraffin-embedded
sections. Among 17 patients, 11 had CTCL-cd without subcutaneous panniculitis-
like T-cell lymphoma (SPTCL) features and six had CTCL-cd with SPTCL features.
Immunophenotypically, some significant differences were found in CD8 and CD56
positivity between our patient series of CTCL-cd patients with SPTCL features and
SPTCL-cd patients described in the previous literature. A univariate analysis of 17
CTCL-cd patients showed that being more than 60 years old, presence of visceral
organ involvement, and small-to-medium cell size were poor prognostic factors. In
addition, the 5-year overall survival rate was 42.4% for the CTCL-cd patients with-
out SPTCL features and 80.0% for those with SPTCL features. Consequently, there
was a strikingly significant difference in overall survival among SPTCL, CTCL-cdwith
SPTCL features and CTCL-cd without SPTCL features (P = 0.0005). Our data suggests
that an indolent subgroup may exist in CTCL-cd. Studies on more cases, including
those from other countries, are warranted to delineate the clinicopathological
features and the significance in these rare lymphomas.
P rimary cutaneous T-cell lymphoma (CTCL) is currentlydefined as a heterogeneous group of lymphoproliferative
disorders characterized by localization of neoplastic T-cells in
skin. Primary cutaneous cd T-cell lymphoma (PCGD-TCL) is
derived from mature activated cytotoxic cd T-cells.(1) Whereas
CTCL of the cd phenotype (CTCL-cd) have poorer prognosis
and follow a more aggressive clinical course than those for
CTCL of the ab phenotype (CTCL-ab),(2) the World Health
Organization–European Organization for Research and Treat-
ment of Cancer 2005 classified CTCL-cd as “provisional,”(3)
and in 2008 PCGD-TCL was categorized by the WHO as a
rare subtype of CTCL.(1) This group includes subcutaneous
panniculitis-like T-cell lymphoma (SPTCL) of the cd pheno-
type for the same reason. This feature is very specific to cuta-
neous tissue because hepatosplenic T-cell lymphoma and
enteropathy-associated T-cell lymphoma (EATL) have poor
prognosis irrespective of T-cell receptor (TCR) phenotype.(4–6)
Therefore, it is becoming increasingly important to classify
CTCL as either ab T-cells or cd T-cells.
Although TCRcd is a strong prognostic factor of
decreased survival,(2) testing of tumor cells for TCRb nega-
tivity and expression of CD56, or sometimes additional test-
ing for TCRd1 positivity in frozen sections has helped to
identify the TCRcd phenotype in paraffin-embedded tis-
sue.(2,7) Recently, it was found that staining of cd T-cells
could be performed in formalin-fixed paraffin-embedded sec-
tions.(8,9) One report described cases of indolent CTCL-cd
localized to the subcutis,(10) but only TCRb negativity was
checked to determine TCRcd phenotype. Hence, it is still
unknown whether indolent CTCL-cd actually exists. Because
few clinicopathological studies have reported on PCGD-TCL,
we conducted a retrospective study of 17 CTCL-cd patients
from Japan and examined further studies for clinicopatholog-
ical, immunophenotypical and immunogenotypical analysis.
Materials and Methods
Patient selection and clinical data. Histological samples for
47 patients were available from 76 consecutive patients (from
1997 to 2010) selected from the consultation files of the
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Department of Clinical Pathophysiology ⁄Clinical Pathology,
Nagoya University Graduate School of Medicine. Histological
samples for 55 patients were available from 89 consecutive
patients (from 1989 to 2011) selected from the consultation
files of the Department of Pathology, Okayama University
Graduate School of Medicine, Dentistry and Pharmaceutical
Sciences. Four faculty pathologists (TY, SN, KT and SK)
practicing in an active lymphoma pathology service who had
varying degrees of experience in lymphoma pathology
reviewed the records. Of the 102 CTCL cases, 68 were classi-
fied as CTCL-ab, 17 were classified as CTCL-cd as per
TCRab and TCRcd immunostaining, and 17 were indetermin-
able because of exhausted tissue samples. In addition, of the
68 patients classified as CTCL-ab, 15 had SPTCL; of these
15, clinical data records were available for 13 and these 13
patients were enrolled in the study.
Data on age, sex, clinical presentation, staging, therapy and
clinical outcome were obtained by review of the medical
records and from follow-up information provided by the
patients’ physicians and pathologists. The present study was
conducted the with approval of the Institutional Review Board
of Okayama University, Okayama, Japan and the Institutional
Review Board of Nagoya University, Nagoya, Japan. Written
informed consent in accordance with the Helsinki protocol was
obtained from each individual. We also statistically compared
clinical and immunohistological data records of six CTCL-cd
patients with SPTCL features in the present series with those
of 20 SPTCL-cd patients described in the previous litera-
ture.(11)
Immunohistochemistry and in situ hybridization studies. Tis-
sue samples were fixed in 10% formalin and embedded in par-
affin. An automated BOND-MAX stainer (Leica Biosystems,
Melbourne, Vic., Australia) was used to stain the paraffin sec-
tions. The following primary antibodies were used (clone, dilu-
tions): CD20 (L26, 1:200), CD3 (LN10, 1:200), CD5 (4C7,
1:100), CD7 (56C6, 1:50), CD8 (C8 ⁄ 144B, 1:100), CD4 (1F6,
1:40), TIA-1 (2G9, 1:500; Beckman Coulter, Brea, CA, USA)
and GranzymeB (GrB-7, ready to use) (Nichirei, Tokyo,
Japan). Primary monoclonal antibodies raised against the
human TCRb (bF1; TCR1151, 8A3, 1:50 [Thermo Scientific,
Waltham, MA, USA]) and TCR-c chain constant region
(TCR1153, c3.20, 1:80 [Thermo Scientific]) were used to
detect the ab and cd TCR, respectively.(12) In situ hybridiza-
tion with Epstein–Barr virus (EBV)-encoded small RNA
(EBER) probes (INFORM EBER; Leica Biosystems) was used
to detect EBV.
The samples of CD20, CD3, CD10, CD5, CD7, CD8, CD4,
TIA-1,(13) granzyme B(14,15) and EBER antigens were scored
as positive when ≥30% of the lymphoma cells were positively
stained. The samples of TCR c, TCR d and TCR b antigens
were scored as positive when ≥50% of the lymphoma cells
were positively stained.
DNA extraction, PCR amplification and analysis of PCR prod-
ucts. A sample 5 mm in diameter was scratched from the
tumor region of each specimen and dissolved in PCR Golden
Buffer (Applied Biosystems, Foster City, CA, USA). An auto-
mated thermocycler GeneAmp PCR system 9700 (Applied
Biosystems) was used at 94°C for 45 min to extract DNA.
PCR reactions were performed according to the BIOMED-2
Concerted Action protocol.(16) Extracted DNA was denatured
at 95°C for 7 min and followed by 35 cycles of denaturing at
95°C for 30 s, annealing at 60°C for 30 s, and extension at
72°C for 30 s, with a final extension at 72°C for 10 min. The
DNA of the skin biopsy samples was amplified by 2
BIOMED-2 TCRc PCR (sets A and B) and 3 TCRb PCR (sets
A, B and C) according to the original Biomed-2 report. Next,
the ABI PRISM 310 Genetic Analyzer and Gene Mapper soft-
ware version 3.7 (Applied Biosystems) were used to analyze
1 lL of each PCR product, as previously described. The peaks
obtained were regarded as clonal bands when ≥1 discrete peaks
within the intended size range were obtained. Peaks with a
height of ≥3 times the third highest peak were considered to
be positive.(16)
Statistical analysis. Overall survival was calculated from the
date of histological diagnosis until the patient’s death or last
follow-up. The Kaplan–Meier method was used to estimate the
survival curves, and the log rank test was used to perform sta-
tistical comparisons. Univariate analysis of prognostic factors,
clinical features and immunohistological analyses were per-
formed using Fisher’s exact test. The Mann–Whitney U-test
was used to analyze age and tumor size differences among the
groups. A P-value of <0.05 was considered statistically signifi-
cant. Statistical Product and Services Solution software (ver-
sion 14.0; SPSS, Chicago, IL, USA) was used to perform all
statistical analyses.
Results
Pathological findings. Of all 17 CTCL-cd patient samples,
six presented histological patterns similar to those of SPTCL
and 11 presented histologically non-SPTCL features (Figs 1a,
b, 2a). The macroscopic and microscopic features of 17
CTCL-cd patient lesions are shown in Table 1. All six CTCL-
cd with SPTCL patients present as plaques while 11 CTCL-cd
without SPTCL patients present as patches, plaques and
tumors. Of the six CTCL-cd with STPCL features, karyorrhex-
is was observed in all patient samples, necrosis in three, and
ulcer and vascular invasion of small blood vessels in one. Of
the 11 samples from CTCL-cd patients without SPTCL fea-
tures, three presented both superficial and deep dermal lesions,
and seven samples showed partial subcutaneous involvement.
Ulcer, epidermotropism and angioinvasion were observed in
three patient samples, and necrosis in two. The neoplastic cells
were medium to large in size, with coarsely clumped chroma-
tin deposition (Fig. 2a).
Immunohistochemical findings. A summary of the immuno-
histochemical results is shown in Table 2. On the basis of
TCRab and TCRcd immunostaining, 17 patients were classi-
fied as CTCL-cd. One patient expressed both TCRab and
TCRcd. Figures 1j,k,l and 2c,d show the immunohistochemical
results for TCRc, TCRd and TCRb immunostaining. Among
all 17 patient samples, CD3 expression was positive in all but
one sample (Figs 1c, 2b). Ten CTCL-cd samples showed
decreased or negative CD5 expression (Fig. 1d). Cytotoxic
molecules (TIA-1 or granzyme B) were positive in all patient
samples except 1 (Fig. 1 h,i). CD56 expression was negative
except in two patient samples (Fig. 1e). In addition, we dem-
onstrated SPTCL, which was positive for TCRab and negative
for TCRcd (Fig. 3).
Molecular studies. T-cell receptor gene rearrangement analy-
ses were performed in 20 ⁄32 cases. PCR was used to ana-
lyze TCRc and ⁄ or TCRb gene rearrangements in 19 cases.
TCRc gene rearrangement was observed in eight cases, and
TCRb gene rearrangement in 10 (see Tables 3 and 4 and
Table S1).
Clinical features and prognostic factors in 17 cutaneus T-cell
lymphoma of the cd phenotype patients. The various clinical
features of CTCL-cd patients with or without SPTCL features
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are summarized in Tables 3 and 4. The 11 CTCL-cd patients
without SPTCL features comprised nine men and two women
aged 22–79 years (median, 54 years). A median follow-up per-
iod of 28 months was recorded (range, 2–259 months). Clini-
cal data and follow-up data were available for all 11 patients.
As a result of the initial treatment, three patients achieved
complete remission or partial response, three exhibited no
change, four suffered progressive disease and one died of cere-
bral hemorrhage without any treatment. In addition, five
patients experienced relapse or recurrence. All three patients
who responded well to the initial treatments subsequently
experienced relapse or recurrence. Of the 11 patients, nine died
of disease within 121 months after diagnosis.
The six CTCL-cd patients with SPTCL features comprised
two men and four women aged 17–81 years (median,
33 years). The median follow-up period was 35.5 months
(range, 17–136 months). Clinical and follow-up data were
available for all six patients. Four patients achieved complete
remission and survived in remission (67%); of these patients,
one achieved spontaneous regression. One patient is alive, but
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
Fig. 1. Immunostainings of primary cutaneous T-cell lymphoma of the cd phenotype with subcutanous panniculitis-like T-cell lymphoma (SPTCL)
feature in patient no. 14 (a–l) (b–l: original magnification 920 objective). (a) Low-power view showing subcutaneous infiltrates as in SPTCL
(H&E). (b) High-power field of subcutaneous infiltrate reveals medium to large sized lymphoid cells with rimming of neoplastic cells (H&E). (c–l)
Immunohistochemical results. The lymphoid cells were positive for CD3 (c), down expression of CD5 (d), negative for CD56 (e), negative for CD4
(f), positive for CD8 (g), positive for TIA-1 (h), positive for Granzyme B (i), positive for T-cell receptor (TCR) c (j), positive for TCRd (k) and nega-
tive for TCRb (l).
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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details are unknown, and one died of cerebral infarction
17 months after diagnosis.
The results of tests for significance of survival from the uni-
variate analysis are summarized in Table 5. More than
60 years old age, presence of visceral organ involvement, and
small-to-medium cell size were poor prognostic factors.
Although the presence or absence of SPTCL features was not
statistically significant as an indicator of survival, there was a
tendency towards a higher 5-year overall survival rate for the
CTCL-cd patients with SPTCL features than for the CTCL-cd
patients without SPTCL features (P = 0.065). Of these four
clinicopathological prognostic factors of survival for the
CTCL-cd patients, we then examined the impact of SPTCL
features.
The clinical features of our SPTCL patient series are
summarized in Table S1. No significant differences in clinical
severity (e.g. occurrence of bone marrow involvement or
hemophagocytic syndrome) were observed between the SPTCL
Table 1. Macroscopic and microscopic feature of CTCL-cd
Patient Gross finding Size (cm)
Histological characterization
Location Ulcer Epidermotropism Necrosis Angioinvasion Cell size
1 Plaque 1 S ⁄ D     L
CTCL-cd without SPTCL feature
2 Tumor 5.1 S ⁄ D     L
3 Tumor 2.6 S ⁄ D  +  + L
4 Tumor ND S ⁄ D +   + S ⁄ M
5 Patch 2.5 D  +   L
6 Patch 3.3 D     S ⁄ M
7† Patch ND ND ND ND ND ND L
8 Plaque 1 S ⁄ D     S ⁄ M
9 Patch 2 S ⁄ D +    S ⁄ M
10 Plaque ND D +  +  L
11 Tumor 1.5 S ⁄ D  + + + L
12 Tumor 2 S ⁄ D     L
CTCL-cd with SPTCL feature
13 Plaque 0.7 S ⁄ D     L
14 Plaque 30 S ⁄ D     L
15 Plaque 10 S ⁄ D   +  L
16 Plaque 10 S ⁄ D   +  L
17 Plaque, tumor 10 S ⁄ D +  + + L
†A biopsy sample from pharynx of patient no.7 was unable to examine sufficiently. ND, no data; L, large; S ⁄ M, small to medium; D, dermal; S ⁄ D,
subcutaneous to dermal; CTCL, cutaneous T-cell lymphoma; SPTCL, subcutaneous panniculitis T-cell lymphoma.
(a)
(d)
(b) (c)
Fig. 2. Immunostainings of primary cutaneous T-cell lymphoma of the cd phenotype without subcutanous panniculitis-like T-cell lymphoma fea-
ture in patient no. 4 (b–e: original magnification 920 objective). (a) High-power field of cutaneous tumor reveals medium to large sized neoplas-
tic cells infiltrating diffusely (H&E). (b–d) Immunohistochemical results. The lymphoid cells were positive for CD3 (b), positive for T-cell receptor
(TCR) c (c) and negative for TCRb (d).
9>>>>>=
>>>>>;
9>=
>;
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and CTCL-cd with SPTCL groups (Table S2). In addition, the
log rank test revealed no significant differences in the overall
survival distributions by TCR phenotypes (P = 0.6). Moreover,
there was no significant difference in relapse-free survival
between SPTCL and CTCL-cd with SPTCL (P = 0.666). On
the other hand, the CTCL-cd without SPTCL patients revealed
aggressive clinical behavior. As for clinical features, there was
statistical significance in abnormal CT scan result (P = 0.03),
initial therapeutic effect (P = 0.01) and status of latest follow
up (P = 0.0175) (Table S2). The 5-year overall survival rates
of the patients with SPTCL, CTCL-cd with SPTCL features
and CTCL-cd without SPTCL features were 85.7%, 80.0% and
42.4%, respectively. A statistically significant difference was
observed in overall survival among the SPTCL, CTCL-cd with
SPTCL features and CTCL-cd without SPTCL features groups
(P = 0.005; Fig. 4).
Discussion
T-cell lymphomas (TCL) expressing the TCRcd phenotype are
rare; the best known types are hepatosplenic TCL and PCGD-
TCL, although sporadic examples of cd TCL, often extranodal,
are recognized as well.(7,17,18) Among hepatosplenic TCL, the
TCRcd phenotype is much more common than the TCRab
phenotype. A study of the clinical features of hepatosplenic
TCL patients revealed that those with the TCRab phenotype
died within 1 year of diagnosis, which suggested an aggressive
behavior similar to that of the TCRcd patients.(4,19) In addi-
tion, the small and large intestines have been predicted to be
important origin sites of cd TCL. Approximately 80% of
monomorphic variants of EATL (Type II EATL) have
expressed TCRcd.(5) Nevertheless, patients with either the
TCRab or TCRcd phenotype have unfavorable prognoses.(5,6)
The characteristics of CTCL are unique, and the clinical
behavior is not like that of other TCL. The prognosis is signifi-
cantly poorer for patients with CTCL-cd than for those with
ab cutaneous lymphoma.(2) Furthermore, because TCL patients
with SPTCL features who express the TCRcd phenotype
reportedly exhibit poorer prognosis than do those who
express the TCRab phenotype,(2) this disease variant was clas-
sified by the WHO in 2008 as PCGD-TCL. In Willemze et al.
(2008) the 5-year overall survival rates of SPTCL and CTCL-
cd with SPTCL features were 81% and 11%, respectively.(11)
Previous research has shown that other primary cutaneous dis-
orders, such as mycosis fungoides (MF) and lymphomatoid
papulosis type D as well as PCGD-TCL show TCRc expres-
sion.(20) The prognosis of MF is not influenced by TCR sub-
types.(21) In the present study, one patient of 17 CTCL-cd
patient series was clinically suspected to have MF; however,
only a pharyngeal biopsy specimen was available from this
Table 2. Immunophenotypic features of patients with CTCL-cd without SPTCL features, CTCL-cd with SPTCL features and SPTCL
Patient no. CD3 CD4 CD5 CD7 CD8 CD20 CD56 CD79a TIA-1 GranzymeB TCRab TCRcd EBER-ISH
1 + ND + ND    ND + ND  + 
2 + ND  ND +  p+ ND + ND  + 
3 + +  ND    ND  ND  + 
4 + ND + ND p+    + ND  + 
5    ND     + ND  + 
6 + + +     ND + ND  + 
7 + ND + ND p+   ND  ND  + 
8 + ND  ND    ND + ND  + 
9 +    +    +   + 
10 + + +     ND  +  + 
11 + + +     ND  +  + 
12 +  Down ND p+    + +  + 
13 +  Down ND +    + + + + 
14 +  Down ND +    + +  + 
15 + p+ Down ND p+  p+ ND + +  + 
16 +  + ND    ND + +  + 
17 +  Down ND    ND + +  + 
18 + UD + ND     ND + +  
19 +  + ND p+  UD  p+ p+ +  
20 +  + ND +     + +  
21 + UD + ND +    + + +  
22 +  + ND +    + + +  
23 +  + ND +   ND + + +  
24 + + + + p+  p+ ND + p+ +  
25 + + + ND    ND + + +  
26 +  + ND +   ND + + +  
27 + UD + ND p+  p+ ND + + +  
28 +  + ND +   ND + + +  
29 +  + + +   ND + + +  
30 +  + ND    ND +  +  
31 +  + ND +   ND + + +  
32 +  + ND p+  p+ ND + + +  
Down, down expression; ND, not done; p+, partially positive; UD, undetectable.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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patient, and the histological details were unknown. This patient
survived for 121 months after diagnosis, demonstrating long-
term clinical course.
The clinicopathological study of 17 CTCL-cd patients
showed that older age, presence of visceral organ involvement,
small-to-medium cell size and non-SPTCL features were pre-
dictors of worse prognosis. Although age and visceral organ
involvement were reasonable prognostic factors, the finding
that the presence of SPTCL features was a predictor is inter-
esting because previous reports have stated that CTCL-cd with
SPTCL features has an unfavorable prognosis, similar to that
of CTCL-cd without SPTCL features.(11,22)
We confirmed that CTCL-cd patients without SPTCL fea-
tures exhibited extremely poor prognosis, similar to those
reported previously.(23) We found only one report of CTCL-cd
that described spontaneous regression;(24) generally, CTCL-cd
progresses unfavorably. Toro et al.(2) report that individuals
suffering from CTCL-cd with subcutaneous involvement
exhibited apparently poorer prognosis than did those with epi-
dermal or dermal involvement.(2) However, CTCL-cd which
had lesions in subcutaneous tissue and had SPTCL features
were found to have better prognosis in the present study.
In the present study, all six CTCL-cd patients presented
tumors with SPTCL features showed remarkably indolent
(a) (b) (c)
(d) (e) (f)
(g)
(j) (k)
(h) (i)
Fig. 3. Immunostainings of subcutanous panniculitis-like T-cell lymphoma in patient no. 18 (a–k) (b–k: original magnification 920 objective).
(a) Low-power view of a punch biopsy. Subcutaneous infiltration of neoplastic cells are seen (H&E). (b) High-power field reveals medium to large
sized atypical lymphoid cells with rimming of neoplastic cells (H&E). (c–k) Immunohistochemical results. The lymphoid cells were positive for CD3
(c), positive for CD5 (d), negative for CD56 (e), negative for CD4 (f), positive for CD8 (g), positive for TIA-1 (h), positive for Granzyme B (i), posi-
tive for T-cell receptor (TCR) b (j) and negative for TCRc (k).
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behavior, and there were no differences in the basic clinical
features, overall survival and relapse-free survival between the
SPTCL patients and those with CTCL-cd with SPTCL fea-
tures. A recent report from the USA describes five cases of
CTCL-cd with SPTCL features that presented indolent clinical
behavior,(10) which supports the findings of our study. Bone
marrow involvement and hemophagocytic syndrome were sig-
nificantly less frequent among our six patients than among the
patients reported in the literature (data not shown).(11) Further-
more, CTCL-cd with SPTCL showed a tendency towards bet-
ter response to initial treatment: five of six CTCL-cd patients
with SPTCL were alive at the time of last follow up, and four
of them showed complete responses. These results suggest that
the characteristics of CTCL-cd with SPTCL are different from
those previously reported for CTCL-cd. According to
Rodrıgues–Pinilla et al. (2013), expression of TCRc is not a
poor prognostic factor by itself, which might support our find-
ing.(20) However, there might have been some differences in
natural history and treatment response between the patients in
the present study and the CTCL-cd patients. We need to exam-
ine further multinational studies in this disease category. One
CTCL-cd patient sample with SPTCL features expressed both
TCRab and TCRcd. Such TCRab ⁄cd double-positive cases
have been reported previously, including PCGD-TCL, MF,
lymphomatoid papulosis and extranodal NK ⁄T cell lym-
phoma.(20,25) It is known that 4% of cd T-cells in peripheral
blood have TCRb rearrangement.(20) However, it is not clear
whether double-positive tumor cells are derived from these cd
T-cells in peripheral blood or suffer cytogenetic abberation.
T-cell receptors with a cytotoxic phenotype often express
NK cell-associated antigens, such as CD56.(26) Gene expres-
sion profiling revealed that peripheral TCL-cd is very similar
to NK-cell lymphoma, but it is distinct from peripheral TCL-
ab and hepatosplenic TCL.(27) CD56 expression is reported to
Table 5. Univariate analysis of CTCL-cd
Clinicopathological
characteristics
N 5-year OS P
Clinical profile
Age
<60 10 64.0 0.036
≧60 7 48.0
Gender
Male 10 40.0 0.179
Female 7 85.7
Lesion
Single 3 66.7 0.962
Multiple or general 14 53.6
Tumor size
<5 5 75.0 0.525
≧5 5 53.3
Lymph node involvement
+ 11 44.4 0.301
 6 57.3
Visceral involvement
+ 3 0 0.016
 14 67.3
LDH above normal
+ 10 48.0 0.824
 5 50.0
B symptoms
+ 5 40.0 0.681
 12 54.7
Clinical stage
I 4 75.0 0.546
II 3 65.7
III 1 ND
IV 8 37.5
TNM
T1 4 50.0 0.534
T2 3 0
T3 8 50.0
Histological profile
Location
Dermal 2 50.0 0.534
Dermal to subcutaneous 14 56.8
Ulceration
+ 4 0 0.166
 13 67.3
Epidermotropism
+ 3 66.7 0.971
 13 65.3
Tumor necrosis
+ 5 26.7 0.618
 11 70.1
Angioinvasion
+ 4 25.0 0.318
 12 66.8
Cell size
Small to medium 4 0 0.041
Large 13 65.3
SPTCL feature
+ 6 80.0 0.065
 11 42.4
CTCL, cutaneous T-cell lymphoma; ND, no data; OS, overall survival;
SPTCL, subcutaneous panniculitis-like T-cell lymphoma.
Fig. 4. Overall survival of primary cutaneus T-cell lymphoma of the
cd phenotype (CTCL-cd) without subcutaneous panniculitis-like T-cell
lymphoma (SPTCL) features, CTCL-cd with SPTCL features and SPTCL. A
statistically significant difference was observed in overall survival
among the SPTCL, CTCL-cd with SPTCL features and CTCL-cd without
SPTCL features groups (P = 0.005).
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be helpful for the differential diagnosis of SPTCL and CTCL-
cd with SPTCL features when the appropriate staining method
for TCRcd is not known.(7,23) Willemze et al. (2008) report
the clinicopathological factors that distinguish between SPTCL
and CTCL-cd with SPTCL features. Most CTCL-cd patients
with SPTCL features are CD56 positive, but SPTCL patients
are CD56 negative.(11) In the present study, only one of the six
CTCL-cd patients with SPTCL features was CD56 positive,
and CD56 positivity was not significantly different between
SPTCL and CTCL-cd with SPTCL features (Table S3). There
was some statistical significance in CD8 and CD56 positivity
between six CTCL-cd patients with SPTCL features in the
present series and 20 SPTCL-cd patients described in the pre-
vious literature (data not shown).(11) In our present series of
CTCL-cd with SPTCL features, five of six samples revealed
downregulated CD5 expression, which is an important immu-
nophenotypical feature of cd TCL (Table S3). These results
suggest that CD5 downregulation is a common feature of
CTCL-cd with SPTCL features.
In Japan, treatment regimens and guidelines are now being
established for different subtypes of CTCL. According to the
clinical practice guidelines for cutaneous lymphoma, after the
pathological diagnosis of SPTCL is established, the clinical
stage is then determined as per TNM classification,(28) revised
Ann Arbor classification and Cotswolds classification. When
the lesion is localized to a small region without any clinical
symptoms, radiotherapy can be considered. Oral steroids or
immunosuppressive therapy can be considered as the first
choice when there is no poor prognostic factor involved, such
as low white blood cell count, high lactate dehydrogenase
levels or complication of hemophagocytic syndrome.(11,29,30)
However, in the present study, none of the patients with
SPTCL or CTCL-cd with SPTCL features who presented with
the aforementioned parameters died. At present, the preferred
treatment for aggressive CTCL is multiple combination che-
motherapy. Another choice is high-dose chemotherapy fol-
lowed by hematopoietic stem cell transplantation. Clinicians
should carefully follow up when the clinical progression of
CTCL-cd with SPTCL features is indolent. We need to accu-
mulate more cases of CTCL-cd by using the immunohisto-
chemical technique on paraffin-embedded sections and conduct
further clinicopathological studies to determine the real fre-
quency of CTCL-cd and its clinical behavior.
In conclusion, although a few case reports have described
indolent cd TCL, we unexpectedly observed that the patients
of the tumors with SPTCL features reveal indolent clinical
behavior. Some cases of CTCL-cd with SPTCL features might
have different characteristics from those of CTCL-cd without
SPTCL features and have more indolent clinical courses than
those previously described for SPTCL-cd. In addition, there
may have been interracial differences between the Asian and
European ⁄American CTCL-cd patients with SPTCL features.
Future studies on more cases including molecular genetic
investigations are required to further elucidate the pathogenesis
and behavior of these categories.
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